A health worker handles a vial of the Sinopharm Group Co COVID-19 vaccine in the Adult Vaccination Center at the Dow University Hospital in Karachi, Pakistan, on Feb 3, 2021. (PHOTO / AFP)

BEIJING - Two COVID-19 vaccines developed by subsidiaries of China National Pharmaceutical Group (Sinopharm) have hit a combined 100 million doses of supply around the world, a Sinopharm affiliate said late on Friday.

READ MORE: Sinopharm's COVID-19 vaccine proves 79.34% effective

Over 80 million doses of the two vaccines were administered, China National Biotec Group Company (CNBG) said on social media.

Sinopharm had said it could reach an annual capacity of 1 billion doses in 2021 and aims to expand capacity to 3 billion doses per year, without specifying the timeframe for the target.

Another Chinese vaccine maker Sinovac Biotech said on Monday it had supplied 160 million doses of its COVID-19 vaccine to 18 countries and regions, including China, with over 70 million shots injected.

ALSO READ: Chinese-made vaccines help Asian nations combat COVID-19

The three vaccines, along with a fourth vaccine from CanSino Biologics Inc, have been approved in China for general public use. A fifth vaccine developed by the Institute of Microbiology Chinese Academy of Sciences has gained clearance for limited emergency use.